← All trials
NCT04511416
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2020
- Primary completion
- Sep 30, 2025
- Completion date
- Dec 31, 2025
- First posted
- Aug 13, 2020
- Last posted
- Aug 13, 2020
- Enrollment
- 242
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Garvan Institute of Medical ResearchLead sponsor
- National Health and Medical Research Council, AustraliaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.